Evaluation of D-chiro-inositol Treatments

Lo.Li.Pharma

Status: Completed

Conditions: Asprosin; Insulin; Inositol; Ovulation; Testosterone

Treatments: Dietary Supplement: D-chiro-inositol

Study type: Interventional

Funder types: Industry

Identifiers

NCT05448378

DCI-Evaluation

Details and patient eligibility

About

Healthy women will take tablets containing 600 mg D-chiro-inositol twice per day for one month. We will evaluate metabolic and hormonal.parameters, as insulienmia, glycemia, estradiol, testosterone.

Enrollment: 10 patients

Sex: Female

Ages: 18 to 50 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Good state of health;
• Regular menstrual cycle.

Exclusion criteria

• pregnancy;
• delivery in the previous 6 months;
• currently breastfeeding;
• menopause;
• alcohol or drug abuse;
• insulin resistance defined as HOMA-IR index greater than or equal to 2.5;
• other medical morbidities, such as hypertension, PCOS, or diabetes;
• oligomenorrhea or amenorrhea;
• current treatment with corticosteroids or hormones (oral contraceptives, estrogensic, progestogensin);
• use of GnRH analogues, SERMs, or SPRMs within the previous 6 months.

Trial design

Primary purpose: Supportive Care

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

10 participants in 1 patient group

D-chiro-inositol

Experimental group

Description:

Patients will take D-chiro-inositol. We will make two blood sampling, at the baseline and after one-month treatment

Treatment:

Dietary Supplement: D-chiro-inositol